Great Point Partners LLC
- SEC CIK
- 0001281446
- Latest filing
- Aug 14, 2026
Holdings in Q3 2022
Holdings as of Sep 30, 2022, filed Nov 14, 2022. Long positions only; changes compare share counts with Q2 2022.
- Positions
- 40
- +7 vs. Q2 2022
- Portfolio value
- $415.3M
- +$27.2M (+7.0%) vs. Q2 2022
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| XENEXenon Pharmaceuticals Inc. | COM | 850,000 | $30.7M | 7.4% | −254,334−23.0% | Reduced | History |
| JAZZJazz Pharmaceuticals plc | SHS USD | 215,000 | $28.7M | 6.9% | +25,000+13.2% | Added | History |
| PNTPOINT Biopharma Global Inc. | COM | 3,560,984 | $27.5M | 6.6% | +1,140,483+47.1% | Added | History |
| ALPNAlpine Immune Sciences, Inc. | COM | 3,448,521 | $24.8M | 6.0% | +2,909,702+540.0% | Added | History |
| TVTXTravere Therapeutics, Inc. | COM | 966,108 | $23.8M | 5.7% | −5,125−0.5% | Reduced | History |
| HRTXHeron Therapeutics, Inc. | COM | 5,645,161 | $23.5M | 5.7% | +5,645,161 | New | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 1,551,719 | $22.5M | 5.4% | +21,719+1.4% | Added | History |
| PLRXPliant Therapeutics, Inc. | COM | 1,041,737 | $21.8M | 5.2% | +684,474+191.6% | Added | History |
| RLMDRelmada Therapeutics, Inc. | COM | 510,000 | $18.9M | 4.5% | −190,000−27.1% | Reduced | History |
| ACRSAclaris Therapeutics, Inc. | COM | 1,019,282 | $16.0M | 3.9% | −63,718−5.9% | Reduced | History |
| PCVXVaxcyte, Inc. | COM | 600,000 | $14.4M | 3.5% | −385,153−39.1% | Reduced | History |
| LKFTLakefront Biotherapeutics NV | SPON ADR | 306,411 | $13.1M | 3.1% | −53,589−14.9% | Reduced | History |
| ABOSAcumen Pharmaceuticals, Inc. | COM | 1,200,000 | $12.0M | 2.9% | −315,000−20.8% | Reduced | History |
| ALKSAlkermes plc. | SHS | 507,500 | $11.3M | 2.7% | +145,864+40.3% | Added | History |
| SGENSeagen Inc. | COM | 76,500 | $10.5M | 2.5% | +76,500 | New | History |
| BBIOBridgeBio Pharma, Inc. | COM | 1,050,000 | $10.4M | 2.5% | +1,050,000 | New | History |
| CINCCinCor Pharma, Inc. | COM | 301,324 | $9.89M | 2.4% | −367,876−55.0% | Reduced | History |
| VTYXVentyx Biosciences, Inc. | COM | 269,967 | $9.43M | 2.3% | −119,256−30.6% | Reduced | History |
| TCDATricida, Inc. | COM | 870,000 | $9.12M | 2.2% | −294,763−25.3% | Reduced | History |
| RAPTRAPT Therapeutics, Inc. | COM | 315,000 | $7.58M | 1.8% | +315,000 | New | History |
| URGNUroGen Pharma Ltd. | COM | 873,424 | $7.27M | 1.7% | 00.0% | Unchanged | History |
| REPLReplimune Group, Inc. | COM | 390,000 | $6.74M | 1.6% | +390,000 | New | History |
| MDGLMadrigal Pharmaceuticals, Inc. | COM | 95,500 | $6.21M | 1.5% | +95,500 | New | History |
| MISTMilestone Pharmaceuticals Inc. | COM | 674,656 | $6.20M | 1.5% | +674,656 | New | History |
| ETNB89bio, Inc. | COM | 955,000 | $5.53M | 1.3% | −445,000−31.8% | Reduced | History |
| GBIOGeneration Bio Co. | COM | 825,077 | $4.38M | 1.1% | +825,077 | New | History |
| NGMNGM Biopharmaceuticals Inc | COM | 316,256 | $4.14M | 1.0% | +316,256 | New | History |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 492,000 | $3.82M | 0.9% | +60,000+13.9% | Added | History |
| IMCRImmunocore Holdings plc | ADS | 78,527 | $3.69M | 0.9% | +78,527 | New | History |
| LRMRLarimar Therapeutics, Inc. | COM | 1,135,000 | $3.63M | 0.9% | +1,135,000 | New | History |
| DTILPrecision Biosciences Inc | COM | 2,710,805 | $3.52M | 0.8% | −3,044,591−52.9% | Reduced | History |
| CBAYCymaBay Therapeutics, Inc. | COM | 799,439 | $2.80M | 0.7% | +799,439 | New | History |
| Pieris Pharmaceuticals Inc720795103 | COM | 1,965,449 | $2.26M | 0.5% | −547,051−21.8% | Reduced | – |
| ICPTIntercept Pharmaceuticals, Inc. | COM | 105,000 | $1.47M | 0.4% | +105,000 | New | History |
| Gracell Biotechnologies Inc38406L103 | SPONSORED ADS | 449,049 | $1.45M | 0.3% | +449,049 | New | – |
| DNTHDianthus Therapeutics, Inc. | COM | 1,019,091 | $1.44M | 0.3% | −150,909−12.9% | Reduced | History |
| NKTRNektar Therapeutics | COM | 447,820 | $1.43M | 0.3% | −2,702,180−85.8% | Reduced | History |
| DAWNDay One Biopharmaceuticals, Inc. | Stock | 70,621 | $1.42M | 0.3% | +70,621 | New | History |
| SYRESpyre Therapeutics, Inc. | COM | 2,500,000 | $1.31M | 0.3% | 00.0% | Unchanged | History |
| SLNSilence Therapeutics plc | ADS | 68,915 | $692.0K | 0.2% | −332,534−82.8% | Reduced | History |
Sold out since Q2 2022 (8)
Positions held at the end of Q2 2022 that are gone from this filing.
| Security | Class | Shares in Q2 2022 | Value in Q2 2022 | % of portfolio in Q2 2022 | History |
|---|---|---|---|---|---|
| CYTKCytokinetics Inc | COM NEW | 610,000 | $24.0M | 6.2% | History |
| KRTXKaruna Therapeutics, Inc. | COM | 149,000 | $18.9M | 4.9% | History |
| SRPTSarepta Therapeutics, Inc. | COM | 193,900 | $14.5M | 3.7% | History |
| KNSAKiniksa Pharmaceuticals International, plc | COM CL A | 1,204,028 | $11.7M | 3.0% | History |
| ANABAnaptysbio, Inc | COM | 453,118 | $9.20M | 2.4% | History |
| NBIXNeurocrine Biosciences Inc | Stock | 75,000 | $7.31M | 1.9% | History |
| Avidity Biosciences, Inc.05370A108 | COM | 500,000 | $7.26M | 1.9% | – |
| KDNYChinook Therapeutics, Inc. | COM | 336,731 | $5.89M | 1.5% | History |